Full Text View
Tabular View
No Study Results Posted
Related Studies
The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin
This study has been completed.
First Received: September 2, 2008   Last Updated: September 4, 2008   History of Changes
Sponsors and Collaborators: University of Edinburgh
Umeå University
Information provided by: University of Edinburgh
ClinicalTrials.gov Identifier: NCT00745693
  Purpose

The purpose of this study is to identify the role of endothelin 1 (a natural vasoconstrictor) in the adverse vascular effects demonstrated after exposure to air pollution


Condition Intervention
Coronary Disease
Drug: Endothelin-1
Drug: BQ-123 and BQ-788

MedlinePlus related topics: Air Pollution Coronary Artery Disease
Drug Information available for: BQ 123 BQ 788
U.S. FDA Resources
Study Type: Interventional
Study Design: Basic Science, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Crossover Assignment
Official Title: The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin

Further study details as provided by University of Edinburgh:

Primary Outcome Measures:
  • Change in forearm blood flow following infusion of endothelin-1 or the endothelin receptor antagonists BQ-123 & BQ-788 [ Time Frame: 2 hours after exposure ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • 24 hour mean blood pressure (ambulatory monitoring) [ Time Frame: 24 hours following the exposure ] [ Designated as safety issue: No ]
  • Systemic endothelin-1 and big endothelin-1 concentrations [ Time Frame: At baseline, and immediately, 1, 2, 3, 4, 6 and 24 hours after exposure ] [ Designated as safety issue: No ]
  • Changes in arterial stiffness (pulse-wave velocity) [ Time Frame: During and for the 1 hour after the exposure ] [ Designated as safety issue: No ]

Enrollment: 15
Study Start Date: March 2008
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
Drug: Endothelin-1
Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
2: Experimental
1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
Drug: BQ-123 and BQ-788
1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
3: Experimental
1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
Drug: Endothelin-1
Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
4: Experimental
1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
Drug: BQ-123 and BQ-788
1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography

Detailed Description:

Air pollution is a major problem, and can be linked to around 5% of all deaths worldwide each year. There are strong associations between air pollution exposure and heart disease but we do not yet understand how these harmful effects are mediated. Understanding this mechanism is likely to have a major impact on the way we treat patients with heart disease and have the potential to shape future environmental health policy. The upregulation of Endothelin-1 provides a plausible mechanism for these harmful effects, and we plan to investigate this in more depth in the human forearm following exposure to diesel exhaust.

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male volunteers

Exclusion Criteria:

  • Use of regular medication
  • Cigarette smoking
  • Significant occupational exposure to air pollution
  • Intercurrent illness
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00745693

Locations
Sweden, Västerbottens
Umeå University
Umeå, Västerbottens, Sweden, SE-901 87
Sponsors and Collaborators
University of Edinburgh
Umeå University
Investigators
Principal Investigator: Jeremy P Langrish, MB BCh MRCP University of Edinburgh
Study Director: Anders Blomberg, MD Umeå University
Study Director: Thomas Sandström, MD Umeå University
Study Director: David E Newby, MD FRCP University of Edinburgh
  More Information

Publications:
Responsible Party: University of Edinburgh ( Dr Jeremy Langrish )
Study ID Numbers: Res08/A116
Study First Received: September 2, 2008
Last Updated: September 4, 2008
ClinicalTrials.gov Identifier: NCT00745693     History of Changes
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by University of Edinburgh:
Endothelin
Air pollution
Diesel exhaust
Vascular function
exposure

Study placed in the following topic categories:
Arterial Occlusive Diseases
Coronary Disease
BQ 788
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Cardiovascular Agents
Cyclo(Trp-Asp-Pro-Val-Leu)
Arteriosclerosis
Ischemia
Antihypertensive Agents
Coronary Artery Disease

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Arteriosclerosis
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Coronary Disease
BQ 788
Therapeutic Uses
Cardiovascular Diseases
Cyclo(Trp-Asp-Pro-Val-Leu)
Coronary Artery Disease

ClinicalTrials.gov processed this record on May 07, 2009